Stock Hero Advertisement SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator mick, Foxwoods Man, drkazmd65, maverick1856
Search This Board:
Last Post: 4/25/2015 4:57:33 PM - Followers: 160 - Board type: Free - Posts Today: 0

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/



Products In Development

Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CANCER - MULTIKINE

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
  2. The scientific, clinical, and commercial development of the medicine and
  3. CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine® (Leukocyte Interleukin, Injection):

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Byron Biopharma
      a. Agreement Signed March 2009  
      b. Territory - Republic of South Africa  
      c. Revenue Share  
  2. Teva Pharmaceuticals Industries Ltd.
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  
  3.  
  4. Orient Europharma Co. Ltd.
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  
  5.  
  6. IDC-GP Pharm LLC 
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  
  7.  

Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.




http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVM
Current Price
Volume:
Bid Ask Day's Range
Wiki
CVM News: Proxy Statement (definitive) (def 14a) 04/21/2015 12:21:56 PM
CVM News: Amended Annual Report (10-k/a) 04/17/2015 05:18:44 PM
CVM News: Statement of Changes in Beneficial Ownership (4) 04/13/2015 05:18:47 PM
CVM News: Statement of Changes in Beneficial Ownership (4) 04/13/2015 05:14:52 PM
CVM News: Statement of Changes in Beneficial Ownership (4) 04/13/2015 05:11:21 PM
PostSubject
#6818  Sticky Note CEL-SCI (NYSE: CVM) is the most undervalued Phase maverick1856 02/27/15 01:26:17 PM
#6737  Sticky Note And then there were 20,.... drkazmd65 02/19/15 11:36:47 AM
#5747  Sticky Note They keep coming!! Foxwoods Man 04/02/14 08:51:19 AM
#7056   No argument here..... Foxwoods Man 04/25/15 04:57:33 PM
#7055   I think in a year or less the Turney 04/25/15 03:24:54 PM
#7054   I would probably put zip on that aftermarket Foxwoods Man 04/25/15 02:12:44 PM
#7053   I'm not sure what weight to give to tprosuper 04/25/15 12:00:35 PM
#7052   After hours shows down on low volume 0.07 Foxwoods Man 04/25/15 09:03:13 AM
#7051   well written piece on CVM and other players Turney 04/24/15 05:37:21 PM
#7050   As I posted before, BIRDFLU in USA is Turney 04/24/15 04:49:42 PM
#7049   Only thing I have seen is an article drkazmd65 04/24/15 01:25:53 PM
#7048   This is from a couple of days ago... Foxwoods Man 04/24/15 01:22:17 PM
#7047   ...and on decent volume Foxwoods Man 04/24/15 01:18:45 PM
#7046   Any idea what's causing the >13% increase today drkazmd65 04/24/15 01:07:51 PM
#7045   Brave. Rawnoc 04/23/15 10:22:26 AM
#7044   IF the need is big enough all rules Turney 04/22/15 04:33:12 PM
#7043   I believe that LEAPS has not yet progressed Foxwoods Man 04/22/15 02:33:58 PM
#7042   I'm just say'in BIRD FLU IN USA!!! IMO Turney 04/22/15 02:02:18 PM
#7041   Everybody RELAX! this game has played out over Turney 04/22/15 08:17:48 AM
#7040   Oh well, here we are at $.88 already ducruacuteo11 04/20/15 02:20:17 PM
#7039   I find it strange that there is no Foxwoods Man 04/18/15 07:39:45 AM
#7038   Just as I feared, with no arbitration resolution ducruacuteo11 04/17/15 04:19:12 PM
#7037   Am waiting to see how that same set drkazmd65 04/15/15 10:21:22 PM
#7036   Cel-Sci Corp. Common (CVM) mick 04/15/15 12:37:06 PM
#7035   You forget that it takes awhile to learn ducruacuteo11 04/15/15 11:54:28 AM
#7034   I would love it if they really did Foxwoods Man 04/14/15 03:17:02 PM
#7033   It doesn't matter now. A couple rounds ducruacuteo11 04/14/15 03:10:52 PM
#7032   Ok...I was doing some thinking (dangerous) on the Foxwoods Man 04/14/15 07:43:24 AM
#7031   neutral for now/\ mick 04/14/15 12:49:04 AM
#7030   Do you have an opinion on that or Kami_ss 04/13/15 04:04:23 PM
#7029   solid/ Cel-Sci Corp. Common (CVM) mick 04/13/15 02:49:19 PM
#7028   Watching paint dries. I am waiting for ducruacuteo11 04/09/15 03:42:10 PM
#7027   What's your point? Is the blank green ducruacuteo11 04/07/15 01:17:56 PM
#7026   stockcharts.com/c-sc/sc?s=CVM&p=D&b=5&g=0&i=p16807577621&r=1403222953921[ mick 04/07/15 02:15:37 AM
#7025   Most of that selling was mine. LOL! ducruacuteo11 04/06/15 01:35:34 PM
#7024   FYI....I cannot respond to the Private Message Board sab63090 04/06/15 12:15:30 PM
#7023   I agree and it looks like Geert's cost sab63090 04/06/15 11:50:43 AM
#7022   As expected the warrants are taking a decent Foxwoods Man 04/06/15 10:21:26 AM
#7021   He has made some forward looking statements in Foxwoods Man 04/04/15 09:48:21 AM
#7020   I wasn't clear on my statement regarding Geert. ducruacuteo11 04/03/15 03:10:02 PM
#7019   Thanks, I see that now....I was asleep at sab63090 04/03/15 09:24:30 AM
#7018   Just an FYI... Foxwoods Man 04/03/15 08:24:24 AM
#7017   CVM sues for $50M plus..... maverick1856 04/03/15 08:17:59 AM
#7016   Thanks, I eventually found it on "Stock Twits" sab63090 04/03/15 08:16:39 AM
#7015   What else can I expect? Foxwoods Man 04/03/15 08:14:51 AM
#7014   Here is the link to the SEC filing maverick1856 04/03/15 08:08:50 AM
#7013   Foxwoods Man...please provide link as I have looked sab63090 04/03/15 07:20:42 AM
#7012   Thanks for your several posts as I was sab63090 04/03/15 06:50:52 AM
#7011   Yes, dilution is coming.....not on your bandwagon of maverick1856 04/03/15 06:40:48 AM
#7010   In some way, I am disappointed at Geert. ducruacuteo11 04/02/15 08:03:56 PM
#7009   Oh well! My guess was right! ducruacuteo11 04/02/15 06:05:13 PM
#7008   ...and released after the close...with no trading tomorrow...Monday Foxwoods Man 04/02/15 04:52:29 PM
#7007   I forgot the first part....no way they are Foxwoods Man 04/02/15 04:50:54 PM
PostSubject